UnknownPhase 2

Safety Analysis of Intravenous Rapid Infusion of Obinutuzumab in Patients With B-cell Non-Hodgkin's Lymphoma in China

China200 participantsStarted 2022-01-01

Plain-language summary

This study aimed to analyze the safety of 90-min intravenous rapid infusion of obinutuzumab in patients with B-cell non-Hodgkin's lymphoma and to provide evidence for the applicability of rapid infusion regimens in chemotherapy in China.

Who can participate

Age range18 Years – 100 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Clinical diagnosis of B-cell lymphoma and with indications for obinutuzumab treatment * No significant organ damage * ECOG score of 0-2; * Life expectancy ≥ 6 months * Informed consent Exclusion Criteria: * Pregnant or lactating * Serologically tested positive for human immunodeficiency virus or hepatitis B virus infection but had not received treatment * Severe hepatic or renal insufficiency * Severe cardiovascular disease.

What they're measuring

change from baseline infusion-related reactions at cycle 6

Timeframe: at the end of cycle 6(each cycle is 21~28 days)

Trial details

NCT IDNCT05510219

SponsorThe First Affiliated Hospital with Nanjing Medical University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-12-31

Contact for this trial

shuangshuang xing, master

+8613851784715 sryxss@163.com

View on ClinicalTrials.gov More Obinutuzumab trials